✦ LIBER ✦

Bevacizumab in the Treatment of Metastatic Colorectal Cancer (mCRC) in Second- and Third-Line Settings

✍ Scribed by Bruce J. Giantonio

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab in the treatment of metastat

✍ Caprioni, Francesco; Fornarini, Giuseppe 📂 Article 📅 2007 🏛 Future Medicine 🌐 English ⚖ 405 KB

Predictors of the efficacy of FOLFIRI pl

✍ Mitsukuni Suenaga; Satoshi Matsusaka; Masashi Ueno; Noriko Yamamoto; Eiji Shinoz 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 148 KB

Metastatic Colorectal Cancer: First- and

✍ Philippe Rougier; Céline Lepère 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 201 KB

PCN110 COST-MINIMIZATION ANALYSIS OF XEL

✍ AS Zazaa; H AlOmar; SA El-Moursy; M AlFayyadh 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Economic analysis of bevacizumab, cetuxi

✍ Lawrence, Donna; Maschio, Michael; Leahy, Kevin J.; Yunger, Simon; Easaw, Jacob 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 466 KB

PCN38 COST-ANALYSIS OF XELOXVS. FOLFOX-4

✍ LP Garrison; G Giuliani; P Ducournau; A Cirrincione 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB